[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimeramp39s-disease-ad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimeramp39s-disease-ad":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,83,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100562036","phase-1-deep-repetitive-transcranial-magnetic-stimulation-rtms-of-the-precuneus-for-alzheimer-disease-ad-100562036",false,"NCT06597942","Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)","Protocol for Maintaining and Improving Mental Status in Alzheimer's Disease (PROMIS-AD): a Pilot Study of Repetitive Transcranial Magnetic Stimulation of the Precuneus for Alzheimer&Amp;Amp;#39;s Disease","PROMIS-AD","Inclusion Criteria:\n\n* Age 60-100 at the start of the study\n* Established diagnosis of Alzheimer's Clinical Syndrome (which is also met through a diagnosis of Alzheimer's Dementia)\n* Agreement to participate in study and able to complete informed consent process\n* Have a caregiver\u002Fstudy partner who can accompany them to all study visits\n* Have a known alternate surrogate decision-maker (in case needed) who can accompany them to the informed consent visit (this person may be the study partner mentioned above)\n* Screening MMSE score of 18-26\n* Screening GDS score \\<6\n* Either 1) treated with memory-enhancing medication (cholinesterase inhibitor) for at least 2 months, 2) failed trial with no plan to re-trial, or 3) no trial planned during the course of the study for other reasons\n* No change in use of psychotropic medication for the treatment of depression, anxiety, ADHD, or psychosis for 2 weeks prior to the study\n\nExclusion Criteria:\n\n* Participant and\u002For their surrogate are unwilling or unable to provide informed consent\n* Currently pregnant or potentially pregnant\n* Diagnosis of a dementia or cognitive disorder due to a cause other than Alzheimer's Disease\n* Diagnosis of severe Dementia (CDR \\> 2.0) at the start of the study\n* History of substance use disorder currently not in sustained remission\n* Substance misuse within the past 6 months (excluding nicotine or caffeine)\n* History of stroke, traumatic brain injury with loss of consciousness, or other major neurologic disorder (e.g., epilepsy, Huntington's disease, Parkinson's disease)\n* History of seizure disorder or family history of seizure disorder in a first-degree relative\n* Poorly-controlled hypertension, cardiovascular disease, or cerebrovascular disease\n* History of any other major active medical, neurologic, or psychiatric illness affecting cognition (associated with cognitive impairment) or a participant's ability to safely and meaningfully participate in the study\n* Non-fluent in English (not native or functionally-native)\n* Contraindication to TMS or MRI including claustrophobia, MRI-incompatible or unknown metal in body (including facial tattoos with uknown or metallic inks), surgery within 60 days, certain implants (excluding dental fillings), or previous abnormal MRI results.\n* Has previous history of TMS treatment in the past (not TMS naïve)\n* Currently enrolled in a memory-enhancement study\n* Alteration in cognitive-enhancement medication dose within the past 2 months or active plans for dose alteration during the course of the study (previously unplanned changes that occur during the study will be examined on a case-by-case basis)\n* History of treatment with lecanemab, aducanumab, donanemab, or other monoclonal antibody treatment for Alzheimer's Disease (due to lack of knowledge surrounding the impacts of these treatments)\n* Currently or within the past 2 weeks taking any of the following classes of medication:\n\n  * Anticholinergic (e.g., tolterodine, benztropine)\n  * Sedating antihistamines (e.g., diphenhydramine)\n  * any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, mirtazapine).\n  * Benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis\n  * Antiepileptic agents. While not a strict rule out, this will be decided on a case-by-case basis\n  * Antipsychotic agents. While not a strict rule out, this will be decided on a case-by-case basis","ALL","60 Years","100 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects. The main questions this study aims to answer are:\n\n* Is deep rTMS of the precuneus feasible and tolerable in Alzheimer's?\n* Are there signs of positive brain changes in response to deep rTMS?\n* Is deep rTMS potentially efficacious for memory in Alzheimer's? Researchers will compare active stimulation to placebo stimulation while obtaining memory testing and measurements of the brain (imaging, scalp electrode measurements, bloodwork) to see if active treatment works to treat mild-to-moderate probable Alzheimer's Dementia.\n\nParticipants will:\n\n* Engage with memory testing, brain scans, and bloodwork during a comprehensive assessment\n* Visit the clinic 3 times for 12 consolidated rTMS sessions, followed by 4 once weekly maintenance sessions\n* Be offered a full open-label active treatment course after completing their treatment course if they are initially in the placebo group",[29,30,31,32,33,34,35],"Alzheimer&Amp;Amp;#39;s Disease","Alzheimer Disease","Dementia Alzheimer Type","Mild Alzheimer&Amp;Amp;#39;s Disease","Moderate Alzheimer&Amp;Amp;#39;s Disease","Alzheimer&Amp;#39;s Disease (AD)","Alzheimer&Amp;#39;s Dementia",[37,38,39,40],"Clinical Trial","deep repetitive transcranial magnetic stimulation (deep rTMS)","precuneus","Mild-to-Moderate Probable Alzheimer's Dementia","RECRUITING","2026-01-19",{"date":44,"type":45},"2026-01-21","ACTUAL",{"date":47,"type":45},"2024-10-17",{"date":49,"type":22},"2026-10",{"name":51,"class":52},"University of California, Los Angeles","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100577860","discovery-and-validation-of-protein-structural-complexes-in-circulating-biofluids-as-novel-biomarkers-for-early-diagnosis-prognosis-and-therapeutic-management-of-patients-affected-by-neurodegenerative-disorders-100577860","NCT06803784","Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders","* Inclusion Criteria:\n* Inclusion criteria for PD patients.\n\nFor the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli. Affected subjects will be selected according to the criteria proposed by Gelb et al in 1999. This is a very pragmatic scheme based on the presence of four cardinal signs, the response to a test administration of Levodopa and the absence of atypical signs:\n\nA) Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset) one of which must be tremor or bradykinesia; B) Absence of atypical symptoms such as: i) early postural instability, freezing phenomena, cognitive deterioration, hallucinations, pathological involuntary movements, vertical gaze paralysis; ii) proven causes of secondary parkinsonism (focal lesions, drugs, toxic substances); C) Documented response to the use of L-dopa or dapamine agonists (or lack of an adequate therapeutic attempt with L-dopa or dopamine agonists).\n\n* Inclusion criteria forAD patients. Patients will be selected at the Center for Cognitive Disorders and Dementias (CDCD) SCDU Neurology, AOU Maggiore della Carità, Novara. Patients with AD will be included after diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011) and supported by positive biomarkers for amyloidopathy (PET with amyloid tracer or amyloid cerebrospinal fluid dosage).\n* Inclusion criteria for FTD\u002FALS patients. For UPO, patients will be selected at the tertiary center Amyotrophic Lateral Sclerosis - SCDU Neurology, AOU Maggiore della Carità, Novara. Patients with amyotrophic lateral sclerosis will be included following a diagnosis according to the El Escorial criteria - revised (2015): in this regard, only patients with a definite or probable diagnosis supported by laboratory will be included. For patients with FTD, they will be selected at both centers mentioned above with a diagnosis according to the Rascovsky criteria (2011). In this group, the diagnosis will be supported by negative biomarkers for amyloidopathy (PET with amyloid tracer or amyloid cerebrospinal fluid dosage). For patients with concomitant ALS and FTD, the El Escorial criteria (2015) associated with the Strong criteria (2017) will be used.\n\nExclusion Criteria:\n\n* PD PATIENTS\n\n  * pre-existing psychiatric pathologies;\n  * neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, neuromuscular diseases, epilepsy;\n  * diagnosis of dementia;\n* AD\u002FFTD\u002FALS PATIENTS\n\n  * pre-existing psychiatric pathologies;\n  * previous diagnosis of other neurodegenerative neurological diseases;\n  * patients unable to sign informed consent.\n* CONTROLS\n\n  * pre-existing psychiatric pathologies;\n  * neurodegenerative neurological diseases such as Parkinson's, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, neuromuscular diseases, epilepsy;\n  * diagnosis of dementia;\n  * depression;\n  * prolonged intake of anxiolytic, antidepressant, antipsychotic, sleep-inducing, cognitive stimulant drugs.",true,"20 Years",{"count":63,"type":22},110,"OBSERVATIONAL","Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation of misfolded proteins, which are believed to play a key role in synaptic dysfunction and neuronal death. Protein structural complexes in biofluids have been proposed to mirror pathological conditions suggesting their use as biomarkers for NDDs characterized by protein aggregation. In this framework, we plan to: i) collect a large cohort of NDD and prodromal patients and healthy subjects using standardized clinical and genetics procedures; ii) apply a novel method based on genomics, proteomics and bioinformatic analysis to map protein complexes in biofluids; iii) identify novel circulating biomarkers and correlate them to genetic profiling and disease endophenotypes, and; iv) validate the biological properties in human brain tissue and dopaminergic cultures.",[67,68,69,70],"Parkinson Disease","Amyotrophic Lateral Sclerosis (ALS)","Frontotemporal Dementia (FTD)","Alzheimer's Disease (AD)",[72,73],"protein structural complexes in Neurodegenerative diseases","circulating biomarkers for neurodegenerative diseases","2025-03-17",{"date":76,"type":45},"2025-03-18",{"date":78,"type":45},"2025-02-04",{"date":80,"type":22},"2026-12",{"name":82,"class":52},"Neuromed IRCCS",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":60,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":53},"100571111","effects-of-endogenous-gamma-light-stimulation-on-brain-oscillations-in-cognitively-normal-older-adults-100571111","NCT06715995","Effects of Endogenous Gamma Light Stimulation on Brain Oscillations in Cognitively-normal Older Adults","Effects of Endogenous Gamma Light Stimulation on Brain Oscillations in Cognitively-normal Older Adults: a Randomized, Placebo-controlled, Double-blind Study","Inclusion Criteria:\n\n* 1\\. Age over 55 years old.\n* 2\\. The Cognitive Abilities Screening Instrument (CASI) score is within normal ranges adjusted for age and education.\n* 3\\. Participants have no history of severe neurological or psychiatric disorders (such as stroke, epilepsy, depression, migraine, etc.) that could affect cognitive function.\n* 4\\. Participants have not used drugs that may affect cognitive function (e.g., benzodiazepines, anticholinergic medications, etc.).\n* 5\\. Participants with normal or corrected vision (e.g., glasses or contact lenses) to normal levels.\n* 6\\. Voluntary to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* 1\\. Participants enrolled in any cognitive enhancement study within the past two months.\n* 2\\. Participants with a history of disease that could affect cognitive function (e.g., cancer, autoimmune diseases, etc.).\n* 3\\. Pregnant, or planning to become pregnant.","55 Years",{"count":92,"type":22},52,[94],"NA","This study aims to evaluate the effects of endogenous gamma non-flickering light stimulation on resting-state EEG rhythms and cognitive function in cognitively healthy older adults. Specifically, it will assess the immediate and long-term effects of this stimulation on brainwave activity and cognitive performance. The study will explore the potential of gamma light stimulation as a non-pharmacological intervention for cognitive decline in aging populations.",[97,70,98],"EEG Brain Oscillations","Cognitively Normal Older Adults",[100,101,102,103,104,105],"Endogenous gamma","EEG rhythms","Resting-state EEG (rs-EEG)","Alzheimer's disease (AD)","Cognitive function","non-flickering light","2024-11-28",{"date":108,"type":45},"2024-12-04",{"date":110,"type":22},"2024-12-09",{"date":112,"type":22},"2025-09-30",{"name":114,"class":52},"Chang Gung Memorial Hospital",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":53},"100570415","exploration-of-the-efficacy-and-mechanisms-of-lymphaticovenous-anastomosis-in-the-treatment-of-alzheimers-disease-100570415","NCT06706947","Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease","Inclusion Criteria:\n\n1. At least two deputy chief physicians or above, diagnosed with Alzheimer's dementia according to the DSM-5 diagnostic criteria;\n2. Age between 18-80 years old;\n3. The course of the disease is at least 1 year;\n4. MMSE score ≤ 24 points; MoCA score \\\u003C 26\n5. Brain MRI shows hippocampal atrophy;\n6. Patients and their families agree to participate in this project for surgical treatment and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with contraindications for Lymphaticovenous Anastomosis; those allergic to anesthetics and contrast agents (indocyanine green);\n2. Those unable to cooperate with cranial magnetic resonance imaging and scale testing;\n3. Patients simultaneously suffering from schizophrenia, depression, bipolar disorder;\n4. Patients with severe somatic diseases (such as cardiovascular, liver, kidney, gastrointestinal, etc.), infectious diseases, and immune system disorders;\n5. Individuals with serious neurological diseases (such as epilepsy, cerebrovascular diseases, etc.), other types of dementia, mental retardation;\n6. Pregnant or lactating women.","18 Years","80 Years",{"count":124,"type":22},20,[94],"The aim of this clinical trial is to determine whether Lymphaticovenous Anastomosis can treat Alzheimer's disease，in AD patients aged 18-80.he main questions it aims to answer are:\n\n1. Can Lymphaticovenous Anastomosis improve cognitive function, daily living ability, mood, or sleep status in patients with Alzheimer's dementia, demonstrating good therapeutic efficacy?\n2. Does deep Lymphaticovenous Anastomosis lead to changes in peripheral blood biomarker levels, neuroinflammatory responses, and neuroimaging in patients with Alzheimer's dementia?",[70],[129,130,131,132,133],"Lymphaticovenous Anastomosis","cognitive function","therapeutic efficacy","Mechanism","Alzheimer's Disease","NOT_YET_RECRUITING","2024-11-25",{"date":137,"type":45},"2024-11-27",{"date":139,"type":22},"2024-12-01",{"date":141,"type":22},"2025-12-31",{"name":143,"class":52},"Luo Xinxin"]